Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05950945 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

StatusRecruiting
PhasePhase 3
Started2023-12-30
View on ClinicalTrials.gov ↗

Amendment history

2026-06-11
Study Status, Contacts/Locations v19
Study sites86→88
2026-04-07
Study Status, Contacts/Locations v18
Study sitesdetails revised at 5 of 86 sites
2026-02-05
Study Status, Contacts/Locations v17
Study sites84→86
2025-10-31
2 amendments v15-v16
2 re-verifications since 2025-09-08, no change to tracked fields
2025-07-28
Study Status, Contacts/Locations v14
Study sites83→84
Show 13 earlier versions
2025-06-30
Study Status v13
Re-verified, no change to tracked fields
2025-04-28
Study Status, Contacts/Locations v12
Study sites70→83
2025-03-24
Study Status, Contacts/Locations v11
Study sites61→70
2025-01-29
Study Status, Contacts/Locations v10
Study sites54→61
2024-12-23
Study Status, Contacts/Locations v9
Study sites46→54
2024-12-02
Study Status, Contacts/Locations v8
Study sites39→46
2024-10-28
Study Status, Contacts/Locations v7
Study sites24→39
2024-09-24
Study Status, Contacts/Locations v6
Study sites18→24
2024-09-03
Study Status, Contacts/Locations v5
Study sites14→18
2024-07-03
Study Status, Contacts/Locations v4
Study sites12→14
2024-07-02
Study Status, Contacts/Locations v3
Study sites1→12
2024-01-02
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2023-12-31→confirmed 2023-12-30
Study sites0→1
2023-11-29
Study Status v1
Primary completion date2027-10→2027-10-01
Completion date2027-10→2027-10-01
Start date2023-10→2023-12-31
2023-07-10
Original filing
Daiichi Sankyo
69 trials monitored
See 8 trials at risk
Breast Cancer
5,180 trials monitored
See 256 trials at risk
This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor \[HR\]-negative and HR-positive) unresectable and/or metastatic breast cancer.
Trial Details
NCT Number NCT05950945
Lead Sponsor Daiichi Sankyo
Collaborators: AstraZeneca
Conditions Breast Cancer
Enrollment 250 participants
Start Date 2023-12-30
Primary Completion 2027-10-01 (estimated)
Study Completion 2027-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-12